Voget E, Schollmeyer P
MMW Munch Med Wochenschr. 1978 Nov 3;120(44):1467-72.
An overview of the development, actions and clinical applications of cimetidine, a new histamine H2 receptor antagonist, is given with reference to the literature. The experience of various investigators with this drug in the treatment of peptic ulcer disease are compared with each other and further indications described. The present results suggest a high therapeutic efficacy with trifling side effects. The latter is discussed with reference to two of our own observations. As long as the side effects are not sufficiently known, it is recommended that indications should be restricted to serious recurrent ulcer disease, reflux disease, prophylaxis and treatment of acute life-threatening hemorrhages and for palliative therapy of the Zollinger-Ellison syndrome.
参照文献对新型组胺H2受体拮抗剂西咪替丁的研发、作用及临床应用进行了综述。比较了不同研究者使用该药物治疗消化性溃疡疾病的经验,并描述了进一步的适应证。目前的结果表明其治疗效果显著且副作用轻微。结合我们自己的两项观察对副作用进行了讨论。只要对副作用了解不足,建议将适应证限制在严重复发性溃疡疾病、反流性疾病、急性危及生命出血的预防和治疗以及佐林格-埃利森综合征的姑息治疗。